Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Oral delivery of proteins has been hampered by an array of difficulties. However, promising novel oral delivery systems have been developed. 5-CNAC, formulated with the peptide salmon calcitonin, is in phase III clinical trials for the treatment of osteoporosis or osteoarthritis and could become the first marketed oral peptide. This article reviews key findings and implications from studies undertaken to date with this oral formulation. Findings include these: (1) the optimal calcitonin tablet dose is 0.8 mg; (2) 0.8 mg of oral calcitonin is rapidly absorbed, reaching maximum concentration in 15 to 30 minutes, and is eliminated from plasma with a short half-life-9 to 15 minutes; (3) the 0.8-mg tablet is more highly absorbed than the marketed nasal formulation, with biomarker levels indicating significantly greater efficacy in suppression of bone resorption; (4) drug absorption is increased with dosing at least 10 minutes before a meal rather than postprandially and also with 50 mL of water; (5) the optimal timing of dosing for osteoporosis therapy is in the evening to mitigate the circadian peak in bone resorption; and (6) the oral formulations of synthetic and recombinant calcitonin have similar pharmacokinetic and pharmacodynamic properties. These key findings may aid researchers in the development of other oral formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence for Calcitonin—A New Hormone from the Parathyroid That Lowers Blood Calcium
COPP, D. H., CAMERON, E. C., CHENEY, B. A., DAVIDSON, A. G. F., & HENZE, K. G. (1962) · Endocrinology · doi:10.1210/endo-70-5-638 · Cited by 697
Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles
Chalasani, K. B., Russell-Jones, G. J., Jain, A. K., Diwan, P. V., & Jain, S. K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.019 · Cited by 257
Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood
Sørensen, M. G., Henriksen, K., Schaller, S., Henriksen, D. B., Nielsen, F. C., Dziegiel, M. H., & Karsdal, M. A. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0725-9 · Cited by 143
Self-citationManicourt, D., Azria, M., Mindeholm, L., Thonar, E. J. ‐., & Devogelaer, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22075 · Cited by 135
Self-citationBagger, Y. Z., Tankó, L. B., Alexandersen, P., Karsdal, M. A., Olson, M., Mindeholm, L., Azria, M., & Christiansen, C. (2005) · Bone · doi:10.1016/j.bone.2005.04.032 · Cited by 109
Self-citationHilton, J., Dowton, M., Houssami, S., & Sexton, P. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1660213 · Cited by 70
Sondergaard, B., Oestergaard, S., Christiansen, C., Tankó, L. B., & Karsdal, M. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22797 · Cited by 65
Self-citation
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
“This enables the complex to access the higher pH environment in the upper small intestine intact and then dissociate enabling improved systemic absorption (reviewed in Karsdal et al., 2011).”
BackgroundIntestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
Diao, L., & Meibohm, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0079-0 · Cited by 369
Metadata
- Authors
- Karsdal, M. A., Henriksen, K., Bay-Jensen, A. C., Molloy, B., Arnold, M., John, M. R., Byrjalsen, I., Azria, M., Riis, B. J., Qvist, P., & Christiansen, C.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 51
- Issue
- 4
- Pages
- 460-471
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- OpenAlex
- W2095852110
- Cited by
- 87
- References
- 7
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials. https://app.cochat.ai/papers/10.1177/0091270010372625
- The paper
- Karsdal, M. A., Henriksen, K., Bay-Jensen, A. C., Molloy, B., Arnold, M., John, M. R., Byrjalsen, I., Azria, M., Riis, B. J., Qvist, P., & Christiansen, C. (2011). Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270010372625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.